Brief: Roche Reports Positive Phase II Results For Enicepatide
BRIEF-Roche Reports Positive Phase II Results For Enicepatide Sept 22 (Reuters) - ROCHE HOLDING AG ROPC.S:
[AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR] ROCHE ANNOUNCES POSITIVE PHASE II RESULTS FOR DUAL GLP-1/GIP RECEPTOR AGONIST ENICEPATIDE IN PEOPLE LIVING WITH TYPE 2 DIABETES AND OVERWEIGHT OR OBESITY
ANNOUNCES POSITIVE PHASE II RESULTS FOR ENICEPATIDE (CT-388)
ENICEPATIDE 24 MG REDUCES HBA1C BY 4.13% AT 48 WEEKS IN POOR CONTROL PATIENTS
TO INITIATE PHASE III GLYCEMIC-CONTROL AND CARDIOVASCULAR OUTCOMES TRIALS IN H1 2027
90% OF ENICEPATIDE 24 MG PATIENTS MET HBA1C ≤6.5% AT 48 WEEKS; 62% ACHIEVED NORMOGLYCEMIA
ENICEPATIDE SHOWS SAFETY PROFILE CONSISTENT WITH INCRETIN CLASS, NO NEW SAFETY SIGNALS
Source text: ID:nGNEw5Myx
Further company coverage: ROPC.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey